Oakland, N.J., Groningen, The Netherlands, October 5, 2022 – Collagen Matrix, Inc. (“Collagen Matrix”), a global leader in regenerative medicine and a Linden Capital Partners (“Linden”) portfolio company, today announced the acquisition of Polyganics, B.V (“Polyganics”). Polyganics is a medical technology company that develops and manufactures bioresorbable medical devices. The acquisition expands Collagen Matrix’s portfolio […]
Ons bedrijf Polyganics ontwikkelt, produceert en verkoopt wereldwijd biologisch afbreekbare medische producten. Onze producten worden gemaakt van bio-afbreekbare synthetische polymeren. Ze worden door het lichaam afgebroken, waardoor er na een operatie in een later stadium geen chirurgische ingreep meer nodig is om ze te verwijderen. Dat maakt onze producten zeer patiëntvriendelijk, veilig en kostenbesparend. Wat […]
Our company Polyganics is an innovative, privately held medical technology company bringing to market unique bioresorbable devices to facilitate tissue repair and regeneration after surgery. From its ISO 13485-certified manufacturing facility, products are distributed to customers worldwide. Polyganics has recently moved to a new facility at the Zernike Campus, Groningen, which houses its headquarters, state-of-the-art […]
Our company Polyganics is an innovative medical technology company. We develop, manufacture and commercialize worldwide, innovative bioresorbable devices to facilitate tissue repair and regeneration after surgery. We adapt our versatile polymers for different clinical applications, improving surgical outcome and patient recovery. The job As one of our Manufacturing engineers you will be improving our processes […]
Randomized controlled trial in the US and Europe will enable LIQOSEAL to be submitted for FDA approval Groningen, The Netherlands, May 21 2021 – Polyganics, a medical technology company developing, manufacturing and commercializing bioresorbable medical devices, today announced treatment of the first patient in its ENCASE II clinical trial for LIQOSEAL. LIQOSEAL is an easy-to-use, […]
Groningen, The Netherlands, 20 April 2021 – Polyganics, a medical technology company developing, manufacturing and commercializing bioresorbable medical devices, today announces its move to a state-of-the art, purpose-built facility on the Zernike Campus, Groningen. The new building will house Polyganics’ research laboratories, manufacturing and packaging facilities, and its offices. The expansion is essential to accommodate […]
Groningen, The Netherlands, 15 September 2020 – Polyganics, a medical technology company developing, manufacturing and commercializing bioresorbable medical devices, today announced treatment of the first patients in its first-in-human study for ACTISEAL®, its Liver and Pancreas Sealant Patch. The ‘SHIELDS’ trial is a prospective, multicenter study, evaluating the safety and performance of ACTISEAL® in reducing […]
Groningen, The Netherlands, 13 May 2020 – Polyganics, a medical technology company developing, manufacturing and commercializing bioresorbable medical devices, announced today that it has received EUR 1.2 million in funding from the European Fund for Regional Development (EFRO) through the Northern Netherlands Alliance (SNN) and the city and province of Groningen, to support clinical validation […]
Groningen, The Netherlands, 3 March 2020 – Polyganics, a medical technology company developing, manufacturing and commercializing bioresorbable medical devices, announced the ground-breaking of a new facility at the Zernike Campus, Groningen. Polyganics aims to move into its new facility, which will house its headquarters, state-of-the-art research laboratories and expanded manufacturing and packaging facilities, in 2021. […]
Groningen, The Netherlands, 07 January 2020 – Polyganics, a medical technology company developing, manufacturing and commercializing bioresorbable medical devices, announced today that it has obtained CE marking for LIQOSEAL®, its easy-to-use and innovative dural sealant patch, and will launch the device in Europe with immediate effect. Approval of the CE mark is based on outstanding […]
